Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients (Q35596990)

9 August 2017

Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients (English)

1 reference

9 August 2017

1 reference

1 reference

R C F Leonard

1

1 reference

9 August 2017

D Miles

2

1 reference

9 August 2017

R Thomas

3

1 reference

9 August 2017

F Nussey

4

1 reference

9 August 2017

UK Breast Cancer Neutropenia Audit Group

5

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

British Journal of Cancer

9 August 2017

1 reference

9 August 2017

89

1 reference

9 August 2017

11

1 reference

9 August 2017

2062-2068

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6601279

9 August 2017

0 references

cites work

Analyzing current practice patterns: lessons from Amgen's Project ChemoInsight.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376842

Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376842

Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376842

First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376842

Economic analyses of toxicity secondary to anthracycline-based breast cancer chemotherapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376842

The importance of dose intensity in the outcome of chemotherapy

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376842

The calculation of actual or received dose intensity: a comparison of published methods.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376842

Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung Cancer

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376842

"Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808)

12 July 2018

1 reference

12 December 2020

Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma

1 reference

12 December 2020

American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines

1 reference

12 December 2020

Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up

1 reference

12 December 2020

Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. American Society of Clinical Oncology

1 reference

12 December 2020

Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer

1 reference

12 December 2020

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel

1 reference

12 December 2020

Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B

1 reference

12 December 2020

Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Cli

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6601279

1 reference

9 August 2017

1 reference

9 August 2017

1 reference